{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-24-000004","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.507190+00:00","generated_at":"2026-06-05T03:45:47.539086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace reports record 2023 revenue $65.4M (+44% YoY); guides 2024 revenue $73M-$77M","bullets":["Record FY 2023 revenue $65.4M (+44% YoY); Q4 revenue $18.0M (+41% YoY). Net loss improved to $33.0M from $47.1M.","Gross margin improved to 73.6% (FY) from 71.4%; Q4 75.2% vs 68.8%. Cash burn reduced to $3.4M in Q4.","FY 2024 guidance: revenue $73M-$77M (+12-18%), gross margin 72-74%, operating expenses $80M-$84M.","NAUTILUS study for generalized epilepsy completed enrollment and implants for FDA submission; Project CARE pilot initiated.","Cash position $66.5M, long-term debt $57.0M; stock-based comp ~$9.6M in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-24-000004","json":"https://secwatch.observer/filing/0001528287-24-000004.json","markdown":"https://secwatch.observer/filing/0001528287-24-000004.md","text":"https://secwatch.observer/filing/0001528287-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828724000004/0001528287-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828724000004/npce-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:45:47.539086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"481907d75c4b1f67b455cb6166d616ae2da1f118","claim":"NeuroPace Inc reported fourth quarter and full year ended December 31, 2023 results: revenue $18.0 million, net income $6.2 million. Guidance initiated.","evidence_excerpt":"NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million Revenue increased to $18.0 million in Q4 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828724000004/0001528287-24-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$18.0 million"},{"label":"Net income","value":"$6.2 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}